Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Imaging
Published in: Cancer Imaging 1/2024

Open Access 01-12-2024 | Computed Tomography | Research article

Superiority of 18F-FAPI-42 PET/CT in the detection of primary tumor and management of appendiceal neoplasm to 18F-FDG PET/CT and CE-CT

Authors: Ye Dong, Shun Huang, Hubing Wu, Min Cao, Yanchao Huang, Ganghua Tang, Wenlan Zhou

Published in: Cancer Imaging | Issue 1/2024

Login to get access

Abstract

Background

In the present study, we investigated the value of 18F-fibroblast-activation protein inhibitor (FAPI) positron emission tomography/computed tomography (18F-FAPI-42 PET/CT) to preoperative evaluations of appendiceal neoplasms and management for patients.

Methods

This single-center retrospective clinical study, including 16 untreated and 6 treated patients, was performed from January 2022 to May 2023 at Southern Medical University Nanfang Hospital. Histopathologic examination and imaging follow-up served as the reference standard. 18F-FAPI-42 PET/CT was compared to 18F-fluorodeoxyglucose (18F-FDG) PET/CT and contrast-enhanced CT (CE-CT) in terms of maximal standardized uptake value (SUVmax), diagnostic efficacy and impact on treatment decisions.

Results

The accurate detection of primary tumors and peritoneal metastases were improved from 28.6% (4/14) and 50% (8/16) for CE-CT, and 43.8% (7/16) and 85.0% (17/20) for 18F-FDG PET/CT, to 87.5% (14/16) and 100% (20/20) for 18F-FAPI-42 PET/CT. Compared to 18F-FDG PET/CT, 18F-FAPI-42 PET/CT detected more regions infiltrated by peritoneal metastases (108 vs. 43), thus produced a higher peritoneal cancer index (PCI) score (median PCI: 12 vs. 5, P < 0.01). 18F-FAPI-42 PET/CT changed the intended treatment plans in 35.7% (5/14) of patients compared to CE-CT and 25% (4/16) of patients compared to 18F-FDG PET/CT but did not improve the management of patients with recurrent tumors.

Conclusions

The present study revealed that 18F-FAPI-42 PET/CT can supplement CE-CT and 18F-FDG PET/CT to provide a more accurate detection of appendiceal neoplasms and improved treatment decision making for patients.
Literature
1.
Tirumani SH, Fraser-Hill M, Auer R, Shabana W, Walsh C, Lee F, et al. Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review. Cancer Imaging. 2013;13(1):14–25.CrossRefPubMedPubMedCentral
2.
3.
Rossi RE, Luong TV, Caplin ME, Thirlwell C, Meyer T, Garcia-Hernandez J, et al. Goblet cell appendiceal tumors–management dilemmas and long-term outcomes. Surg Oncol. 2015;24(1):47–53.CrossRefPubMed
4.
Mccusker ME, Cote TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973–1998. Cancer. 2002;94(12):3307–12.CrossRefPubMed
5.
Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, Gonzalez-Moreno S, et al. A Consensus for classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26.CrossRefPubMed
6.
Matias-Garcia B, Mendoza-Moreno F, Blasco-Martinez A, Busteros-Moraza JI, Diez-Alonso M, Garcia-Moreno NF. A retrospective analysis and literature review of neoplastic appendiceal mucinous lesions. Bmc Surg. 2021;21(1):79.CrossRefPubMedPubMedCentral
7.
Ruiz-Tovar J, Teruel DG, Castineiras VM, Dehesa AS, Quindos PL, Molina EM. Mucocele of the appendix. World J Surg. 2007;31(3):542–8.CrossRefPubMed
8.
Menassel B, Duclos A, Passot G, Dohan A, Payet C, Isaac S, et al. Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms. Eur J Surg Oncol. 2016;42(4):558–66.CrossRefPubMed
9.
Gundogar O, Kimiloglu E, Komut N, Cin M, Bektas S, Gonullu D, et al. Evaluation of appendiceal mucinous neoplasms with a new classification system and literature review. Turk J Gastroenterol. 2018;29(5):533–42.CrossRefPubMed
10.
Brassil M, Lee R, O’Neill D, Woods G, Moloney BM, Dunne R, et al. Appendiceal tumours - a correlation of CT features and histopathological diagnosis. J Med Imaging Radiat Oncol. 2022;66(1):92–101.CrossRefPubMed
11.
Leonards LM, Pahwa A, Patel MK, Petersen J, Nguyen MJ, Jude CM. Neoplasms of the appendix: Pictorial Review with Clinical and pathologic correlation. Radiographics. 2017;37(4):1059–83.CrossRefPubMed
12.
Rohani P, Scotti SD, Shen P, Stewart JH, Russell GB, Cromer M, et al. Use of FDG-PET imaging for patients with disseminated cancer of the appendix. Am Surg. 2010;76(12):1338–44.CrossRefPubMed
13.
Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62(2):160–7.CrossRefPubMed
14.
Pang Y, Zhao L, Luo Z, Hao B, Wu H, Lin Q, et al. Comparison of (68)Ga-FAPI and (18)F-FDG uptake in gastric, duodenal, and colorectal cancers. Radiology. 2021;298(2):393–402.CrossRefPubMed
15.
Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, et al. The role of (68)Ga-FAPI PET/CT for patients with malignancies of the Lower Gastrointestinal Tract: first clinical experience. J Nucl Med. 2020;61(9):1331–6.CrossRefPubMedPubMedCentral
16.
Al-Ibraheem A, Alyasjeen SF, Abdlkadir AS, Sheikha AA. [(68)Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [(68)Ga]Ga-DOTATOC PET/CT missed. Eur J Nucl Med Mol Imaging. 2023;50(13):4112–3.CrossRefPubMed
17.
Al-Ibraheem A, Al-Qasem S, El KM, Amarin R. 68 Ga-FAPI PET/CT provides a clear picture of a Klatskin Tumor that 18 F-FDG PET/CT missed. Clin Nucl Med. 2023;48(6):e313–5.CrossRefPubMed
18.
Rajaraman V, Meenakshi LA, Selvaraj AJ, Pottakkat B, Halanaik D. Role of 68 Ga-FAPI PET/CT in assessing Hepatobiliary malignancies: a prospective pilot study. Clin Nucl Med. 2023;48(6):e281–8.CrossRef
19.
Al-Ibraheem A, Abdlkadir AS, Alalawi H, Badarneh M. 68 Ga-FAPI PET/CT imaging: unveiling the hidden pitfalls. Clin Nucl Med. 2023;48(11):965–6.CrossRefPubMed
20.
Bentestuen M, Al-Obaydi N, Zacho HD. FAPI-avid nonmalignant PET/CT findings: an expedited systematic review. Semin Nucl Med. 2023;53(5):694–705.CrossRefPubMed
21.
Chen H, Pang Y, Li J, Kang F, Xu W, Meng T, et al. Comparison of [(68)Ga]Ga-FAPI and [(18)F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol. 2022;33(2):1329–41.CrossRefPubMed
22.
Qiu L, Chen Y. (68)Ga-FAPI PET/CT depicted Non-FDG-Avid Metastatic Appendiceal Mucinous Adenocarcinoma. Radiology. 2021;301(1):45.CrossRefPubMed
23.
Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [(18)F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [(68)Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2021;49(8):2833–43.CrossRefPubMed
24.
Spencer BA, Berg E, Schmall JP, Omidvari N, Leung EK, Abdelhafez YG, et al. Performance evaluation of the uEXPLORER Total-Body PET/CT scanner based on NEMA NU 2-2018 with additional tests to characterize PET scanners with a long Axial Field of View. J Nucl Med. 2021;62(6):861–70.CrossRefPubMedPubMedCentral
25.
Tan H, Sui X, Yin H, Yu H, Gu Y, Chen S, et al. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol Imaging. 2021;48(6):1966–75.CrossRefPubMed
26.
Wang L, Tang G, Hu K, Liu X, Zhou W, Li H, et al. Comparison of (68)Ga-FAPI and (18)F-FDG PET/CT in the evaluation of Advanced Lung Cancer. Radiology. 2022;303(1):191–9.CrossRefPubMed
27.
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMed
28.
Gundogan C, Komek H, Can C, Yildirim OA, Kaplan I, Erdur E, et al. Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in the staging and restaging of gastric adenocarcinoma. Nucl Med Commun. 2022;43(1):64–72.CrossRefPubMed
29.
Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G, et al. Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2022;49(2):743–50.CrossRefPubMed
30.
Dong Y, Sun P, Wu H, Zhong J, Cao M, Tang G, et al. PET/CT imaging fibroblast activation protein in initial colorectal cancer: compared to 18F-FDG PET/CT. Nucl Med Commun. 2023;44(11):1011–9.CrossRefPubMed
31.
Carr NJ, Bibeau F, Bradley RF, Dartigues P, Feakins RM, Geisinger KR, et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology. 2017;71(6):847–58.CrossRefPubMed
32.
Minhas A, Hendrickson J, Minhas SA. Frequency and risk factors for Metastasis in newly diagnosed Appendiceal Carcinoma. Cureus. 2021;13(7):e16341.PubMedPubMedCentral
33.
Akbulut S, Sahin TT. Comment on management and prognosis of low-grade appendiceal mucinous neoplasms: a clinicopathologic analysis of 50 cases. Eur J Surg Oncol. 2020;46(12):2338.CrossRefPubMed
34.
Kehagias I, Zygomalas A, Markopoulos G, Papandreou T, Kraniotis P. Diagnosis and treatment of Mucinous Appendiceal Neoplasm presented as Acute Appendicitis. Case Rep Oncol Med. 2016;2016:2161952.PubMedPubMedCentral
35.
Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of Quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22.CrossRefPubMed
36.
Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D, et al. A tumor-imaging Method Targeting Cancer-Associated fibroblasts. J Nucl Med. 2018;59(9):1423–9.CrossRefPubMedPubMedCentral
Metadata
Title
Superiority of 18F-FAPI-42 PET/CT in the detection of primary tumor and management of appendiceal neoplasm to 18F-FDG PET/CT and CE-CT
Authors
Ye Dong
Shun Huang
Hubing Wu
Min Cao
Yanchao Huang
Ganghua Tang
Wenlan Zhou
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cancer Imaging / Issue 1/2024
Electronic ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-024-00706-7

Other articles of this Issue 1/2024

Cancer Imaging 1/2024 Go to the issue

Research article

Value of high frame rate contrast enhanced ultrasound in gallbladder wall thickening in non-acute setting

Research article

Prognostic PET [11C]-acetate uptake is associated with hypoxia gene expression in patients with late-stage hepatocellular carcinoma – a bench to bed study

Research article

Prognostic and predictive value of interstitial lung abnormalities and EGFR mutation status in patients with non-small cell lung cancer

Research article

Enhancing brain metastasis prediction in non-small cell lung cancer: a deep learning-based segmentation and CT radiomics-based ensemble learning model

Research article

MRI evaluation of vesical imaging reporting and data system for bladder cancer after neoadjuvant chemotherapy

Research article

A CT based radiomics analysis to predict the CN0 status of thyroid papillary carcinoma: a two- center study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits